CSI Market
Sign In | Register

Nurix Therapeutics Inc (NRIX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NRIX quarterly Cash Flow →
Tracking cash flow results across Nurix Therapeutics Inc to Nov 30 2021 helps illustrate how Nov 30 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Nov 30 2025)
12 Months 		(Nov 30 2024) (Nov 30 2023) (Nov 30 2022) (Nov 30 2021)
Operating Activities
Income-264.46
Depreciation & amortization8.74
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.09
Share-based Compensation37.97
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Operating Lease Right Of Use Asset Amortization Expense10.12
Increase Decrease In Contract With Customer Liability-36.98
Increase Decrease In Operating Lease Liability-5.07
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities17.31
Increase (Decrease) in Accounts Payable-0.63
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-6.23
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-10.32
Discontinued operations0.00
Net Cash flow from Operating Activities-249.47
Investing Activities
Capital Expenditures-14.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities0.00
Payments to Acquire Marketable Securities-455.69
Real Estate Investments0.00
Proceeds From Sales Of Investments-
Proceeds From Sales Of Marketable Securities-
Proceeds From Maturities Of Marketable Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments617.54
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities147.85
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.23
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-112.10
Payments For Repurchase Of Unvested Early Exercised Stock Options-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations110.90
Proceeds From Stock Options And Warrants Exercised1.65
Proceeds From Issuance Of Common Stock And Warrants234.76
Payments For Repurchase Of Stock Options-
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount0.02
Deferred Issuance Costs Included In Accrued Expenses And Other Liabilities-
Deferred Issuance Costs Recognized Related To Equity Financing-
Vesting Of Early Exercised Stock Options-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Capital Expenditures Incurred But Not Yet Paid1.18
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities238.64
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-263.47
Total Cash Flow137.03
4 historic quarters locked

Sign in to unlock the full Nurix Therapeutics Inc cash flow history.

Sign In Create Free Account

About Nurix Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001549595-26-000016

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License